7-T Magnetic Resonance Imaging in the Management of Brain Tumors

Melanie A Morrison; Janine M Lupo

doi:10.1016/j.mric.2020.09.007

7-T Magnetic Resonance Imaging in the Management of Brain Tumors

Magn Reson Imaging Clin N Am. 2021 Feb;29(1):83-102. doi: 10.1016/j.mric.2020.09.007.

Authors

Melanie A Morrison¹, Janine M Lupo²

Affiliations

¹ Department of Radiology and Biomedical Imaging, University of California, San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143, USA.
² Department of Radiology and Biomedical Imaging, University of California, San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143, USA. Electronic address: janine.lupo@ucsf.edu.

PMID: 33237018
DOI: 10.1016/j.mric.2020.09.007

Abstract

This article provides an overview of the current status of ultrahigh-field 7-T magnetic resonance (MR) imaging in neuro-oncology, specifically for the management of patients with brain tumors. It includes a discussion of areas across the pretherapeutic, peritherapeutic, and posttherapeutic stages of patient care where 7-T MR imaging is currently being exploited and holds promise. This discussion includes existing technical challenges, barriers to clinical integration, as well as our impression of the future role of 7-T MR imaging as a clinical tool in neuro-oncology.

Keywords: Brain tumors; CEST; Glioma; Late effects; Magnetic resonance spectroscopy; Susceptibility-weighted imaging; Ultrahigh-field MR imaging.

Publication types

Review

MeSH terms

Brain / diagnostic imaging
Brain Neoplasms / diagnostic imaging*
Humans
Magnetic Resonance Imaging / methods*

Grants and funding

R01 HD079568/HD/NICHD NIH HHS/United States